Search
Returning search results with filters:
Remove filter for
Category: Health products
Remove filter for
Issue: Health products
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Recall class
Displaying 31 - 45 of 1077 items.
Unauthorized UMARY Hyaluronic Acid Dietary Supplement contains undeclared prescription drugs and may pose serious health risks
AlertPublic advisory | 2024-05-14
REDDY-SAPROPTERIN: Color change & decrease potency
RecallHealth product recall | 2024-05-03
Fake Viagra seized from Jug City store in Scarborough, ON
AlertPublic advisory | 2024-04-26
Importation of Italian-authorized Cisatracurio Hikma 2 mg/mL Ampoules due to the Current Shortage of Canadian-authorized Cisatracurium Omega
AlertHealth professional risk communication | 2024-04-24
Miracle Reds: missing risk statement
RecallHealth product recall | 2024-04-23
PMS-Duloxetine 60 mg: Exceeds acceptable interim intake limit for N-nitroso-duloxetine (NDLX)
RecallHealth product recall | 2024-04-17
PMS-Duloxetine 30 mg: Exceeds acceptable interim intake limit for N-nitroso-duloxetine (NDLX)
RecallHealth product recall | 2024-04-17
I-131 Diagnostic Capsule: Affected lots may have decreased thyroid uptake.
RecallHealth product recall | 2024-04-17
Recall of one lot of JAMP Guanfacine XR 4 mg tablets due to contamination with foreign matter
AlertPublic advisory | 2024-04-12
JAMP-Guanfacine XR 4 mg: Foreign matter
RecallHealth product recall | 2024-04-10
Unauthorized health products seized from Vanette Keast Health Consulting in Red Deer, Alberta may pose serious health risks
AlertPublic advisory | 2024-04-09
Honeywell Eyesaline Emergency Eyewash: deficiencies in Good Manufacturing Practices (GMP)
RecallHealth product recall | 2024-04-04
JAMP-Rabeprazole 20 mg: Affected lot may contain JAMP-Rabeprazole 10 mg
RecallHealth product recall | 2024-04-02
Unauthorized skin lightening and skin treatment products may pose serious health risks
AlertPublic advisory | 2024-03-27
Ezetrol (ezetimibe) and the Risks of Drug-Induced Liver Injury and Severe Cutaneous Adverse Reactions
AlertHealth professional risk communication | 2024-03-27